SCHEMBL1004335

SCHEMBL1004335

Cc1c(F)cc(C(N)=O)cc1F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.57
HDAC6 Q9UBN7 3/20 0.57
PARP1 P09874 4/20 0.43
CES2 O00748 2/20 0.41
CES1 P23141 2/20 0.41
PTPN11 Q06124 1/20 0.40
CYP3A4 P08684 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TSHR P16473 3/20 0.38
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C19 P33261 1/20 0.37
RECQL P46063 1/20 0.37
BLM P54132 1/20 0.37
PMP22 Q01453 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
DGAT1 O75907 1/20 0.36
APOBEC3A P31941 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26340812 0.89 HDAC1 (0.47) HDAC1HDAC6PARP1CES2CES1
SCHEMBL1233573 0.86 HDAC1 (0.44) HDAC1HDAC6PARP1CES2CES1
SCHEMBL19880407 0.82 HDAC1 (0.42) HDAC1HDAC6PARP1CES2CES1
SCHEMBL1799276 0.80 CES2 (0.64) HDAC1HDAC6PARP1CES2CES1
SCHEMBL26626574 0.80 PARP1 (0.49) PARP1CYP3A4SMN1; SMN2TSHRPOLB
SCHEMBL30601690 0.80 PARP1 (0.49) PARP1CYP3A4SMN1; SMN2TSHRPOLB
SCHEMBL19155372 0.79 HDAC1 (0.46) HDAC1HDAC6PARP1CES2CES1
SCHEMBL1105952 0.78 HDAC1 (0.59) HDAC1HDAC6CES2CES1SMN1; SMN2
SCHEMBL13125486 0.78 HDAC1 (0.59) HDAC1HDAC6CES2CES1L3MBTL1
Hydrochloric Acid SCHEMBL6831741 0.78 CES2 (0.61) HDAC1HDAC6PARP1CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303573-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives Grünenthal GmbH (DE) 2023-09-28 US disclosed
WO-2023159307-A1 POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF REPARE THERAPEUTICS INC. (CA) 2023-08-31 WO disclosed
EP-3722284-A1 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES Grünenthal GmbH (DE) 2020-10-14 EP disclosed
WO-2017121647-A1 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES Grünenthal GmbH (DE) 2017-07-20 WO disclosed
US-8778219-B2 Ionic liquids for separation of olefin-paraffin mixtures UT-BATTELLE, LLC (US) 2014-07-15 US disclosed
US-20130338389-A1 IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES UT-BATTELLE, LLC (US) 2013-12-19 US disclosed
US-8535560-B2 Ionic liquids for separation of olefin-paraffin mixtures UT-BATTELLE, LLC (US) 2013-09-17 US disclosed
WO-2011008664-A2 IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES UT-BATTELLE, LLC (US) 2011-01-20 WO disclosed
US-20110015461-A1 Ionic Liquids for Separation of Olefin-Paraffin Mixtures UT-BATTELLE, LLC (US) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338389-A1 IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES POU2F1, POU2F2, POF1B HDAC1 3902/4885HDAC6 4094/4885PARP1 4538/4885
US-20230303573-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives OPRK1, OPRD1, OPRL1 HDAC1 770/4885HDAC6 979/4885PARP1 782/4885
US-20110015461-A1 Ionic Liquids for Separation of Olefin-Paraffin Mixtures POU2F1, POU2F2, POF1B HDAC1 3902/4885HDAC6 4094/4885PARP1 4538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.